시간 외 거래: 7.68 0.03 +0.39%

ImmunityBio Inc (IBRX)

ImmunityBio Inc 주식(IBRX)의 최신 뉴스

ImmunityBio Inc (IBRX)

ImmunityBio Inc 주식(IBRX)의 최신 뉴스

How Is The Market Feeling About ImmunityBio? - Investing.com UK

What the Options Market Tells Us About ImmunityBio - ImmunityBio (NASDAQ:IBRX) - Benzinga

Connecting the Dots of ANKTIVA's Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat ... - Business Wire

(IBRX) Proactive Strategies - Stock Traders Daily

ImmunityBio (NASDAQ:IBRX) Shares Down 4.2% - MarketBeat

Investigation Alert Baxter International, Eagle Pharmaceuticals, BioXcel Therapeutics, and ImmunityBio: Johnson Fistel ... - GlobeNewswire

Investigation Alert Baxter International, Eagle Pharmaceuticals, BioXcel Therapeutics, and ImmunityBio: - EIN News

ImmunityBio (NASDAQ:IBRX) Trading Up 8.9% - MarketBeat

Amid Biotech Pitfalls, this Stock Has Outperformed NVDA in the Last 3 Months - The Tokenist

ImmunityBio Advances On the Anktiva Front - Los Angeles Business Journal

ImmunityBio First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

ImmunityBio (NASDAQ:IBRX) Shares Gap Down to $8.06 - MarketBeat

ImmunityBio: Q1 Earnings Snapshot - Darien Times

Zurcher Kantonalbank Zurich Cantonalbank Has $141000 Stock Position in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World

ImmunityBio (IBRX) Stock Jumps 43.2%: Will It Continue to Soar? - Yahoo Singapore News

ImmunityBio Plans to Use Dunkirk Facility for Producing Cancer-Treating Drug - Chautauqua Today

ImmunityBio (IBRX) Stock Jumps 43.2%: Will It Continue to Soar? - Yahoo News UK

Dunkirk plant part of ImmunityBio plans for drug - Jamestown Post Journal

Dunkirk plant part of ImmunityBio plans for drug - Jamestown Post Journal

170000 Bladder Cancer Vaccine Doses Prepared by ImmunityBio - Precision Vaccinations

ImmunityBio says it's committed to Dunkirk - Buffalo News

ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170000 Doses of ANKTIVA® - Tyler Morning Telegraph

ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170000 Doses of ANKTIVA® - Business Wire

ANKTIVA for Non-Muscle Invasive Bladder Cancer (NMIBC), USA - Clinical Trials Arena

ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170000 Doses of ANKTIVA® - The Bakersfield Californian

ImmunityBio (NASDAQ:IBRX) Shares Down 12.6% - MarketBeat

What's Going On With ImmunityBio Stock? - MSN

Serum Institute of India partners with ImmunityBio for global supply of BCG across all cancer types - BSI bureau

ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin ... - Business Wire

ImmunityBio partners with Serum Institute for cancer treatment supply - Investing.com

Enhanced Bladder Cancer Vaccine Ships 1,000 Doses — Precision Vaccinations News - Precision Vaccinations

ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the ... - Business Wire

Check Out What Whales Are Doing With IBRX - ImmunityBio (NASDAQ:IBRX) - Benzinga

ImmunityBio shares target raised on Anktiva pricing strategy By Investing.com - Investing.com

US FDA approves ImmunityBio's bladder cancer therapy - Yahoo News Canada

What's Going On With ImmunityBio Stock? - ImmunityBio (NASDAQ:IBRX) - Benzinga

FDA approves local company's bladder cancer drug - The Business Journals

ImmunityBio's ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG ... - geneonline

Immunitybio's bladder cancer therapy, Anktiva, gets FDA approval - BioWorld Online

ImmunityBio's FDA Approval and Planned Equity Expansion - TipRanks.com - TipRanks

FDA Approve ImmunityBio Bladder Cancer Therapy - European Pharmaceutical Manufacturer

FDA clears ImmunityBio's bladder cancer drug at 2nd attempt - pharmaphorum

ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non ... - Financial Times

FDA Action Alert: ImmunityBio, Aquestive, XOMA and More - BioSpace

Vanguard Group Inc. Buys 4,342,386 Shares of ImmunityBio, Inc. (NASDAQ:IBRX) - MarketBeat

Eight PDUFA dates on deck in April - BioCentury

Is Immunitybio Inc (IBRX) Stock a Smart Value? - InvestorsObserver

ImmunityBio shares target raised by Piper Sandler on potential approval By Investing.com - Investing.com

Sportradar Group Posts Upbeat Earnings, Joins Kingsoft Cloud, Braskem And Other Big Stocks Moving Higher On Wednesday

2 Stocks Under $20: Immunitybio and Lemonade - Schaeffers Research

IBRX과 유사한 종목